Biomunex Pharmaceuticals has signed a licensing agreement with Sanofi for the development of bi-specific and multi-specific antibody therapeutics.
As part of the deal, Sanofi will use the BiXAb platform of Biomunex to generate and enhance bi-specific and multi-specific antibodies. Sanofi will take responsibility for the research, development, manufacturing and global commercialization activities of new antibody therapeutics.
As per terms of the deal, Biomunex will secure an initial upfront payment and further clinical, regulatory and commercial milestone payments.
Biomunex plug-and-play BiXAb is a universal modular bi-specific and multi-specific format, enabling the platform to format from any pair of monospecific monoclonal antibodies as building blocks in a timely and cost-effective manner. The platform includes all crucial properties, including modularity, better drug-like properties and manufacturability, multi-specificity potential, required for an ideal bi-specific antibody technology. The company is using the platform to develop immunooncology drug candidates with high anti-tumor activity,
The BiXAb platform can also be used to generate bi-specific and multi-specific antibodies in other therapeutic areas, including immune-mediated inflammatory and infectious diseases.
Biomunex founder and CEO Dr Pierre-Emmanuel Gerard said:
This licensing agreement is a major milestone for Biomunex. It demonstrates the high value of the BiXAb technology and is the starting point for our collaboration strategy with pharmaceutical companies to discover and develop cutting-edge bi- and multi-specific antibodies, giving patients new treatment options. We believe that the proceeds from this deal, together with the funding round that we expect to finalize in the near future, will help us accelerate the development of Biomunex’ proprietary BiXAb biand multi-specific antibody programs in immuno-oncology and other therapeutic areas towards clinical development.
Biomunex is a biopharmaceutical firm engaged in the discovery and development of bi-specific and multi-specific antibodies. The firm’s most advanced candidate has showed superior in vitro and in vivo efficacy, and expected to serve as a immunotherapy for several solid tumors such as head-and-neck, gastric and pancreatic cancers.
Its other lead candidate, holds capacity to advance immune checkpoint inhibition, and is being assessed for hematological malignancies.